Under construction – not a live service
Sign in
Not yet taking people in DenmarkNo phase

Reminder App for Bladder Filling in Prostate Cancer Radiotherapy

Tests a reminder app to help men with prostate cancer drink water before radiotherapy.

Plain-language title generated from the registry record
Registry title: A Reminder App to Optimize Bladder Filling in Patients with Prostate Cancer Receiving HYPO-fractionated Radiotherapy

Key facts

Where
Vejle, DenmarkSee the site

Where in Denmark

  • Department of Oncology Vejle Hospital, University Hospital of Southern DenmarkVejle, DenmarkNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University Hospital Schleswig-Holstein
Trial code
NCT06784115
Record updated
20 January 2025
Original description
The primary goal of this study is to assess the impact of an app that reminds patients treated with hypofractionated radiotherapy (HF-RT) for prostate cancer to drink water prior to each radiotherapy session on the number of bladder volumes <200 ml during the HF-RT course and to demonstrate that this number is lower than without using an app (historical control group).Read full original descriptionShow less

A REminder App to Optimize Bladder FILLing in Patients with ProstAte Cancer Receiving HYPO-fractionated Radiotherapy

The primary goal of this study is to assess the impact of an app that reminds patients treated with hypofractionated radiotherapy (HF-RT) for prostate cancer to drink water prior to each radiotherapy session on the number of bladder volumes <200 ml during the HF-RT course and to demonstrate that this number is lower than without using an app (historical control group).

Inclusion: Histologically proven prostate cancer; Indication for definitive HF-RT; Possession of and ability to use a smartphone; Bladder volume at CT-simulation <200 ml; Male gender; Age ≥18 years; Written informed consent; Capacity of the patient to contract.

Exclusion: Radiotherapy of pelvic lymph nodes; Expected non-compliance.

ClinicalTrials.gov NCT06784115